As­traZeneca, Mer­ck score a block­buster ad­vance as Lyn­parza comes through in front­line ovar­i­an can­cer

As­traZeneca’s on­col­o­gy R&D team has suc­cess­ful­ly hit an­oth­er land­mark mile­stone.

The phar­ma gi­ant along with its part­ners at Mer­ck are drum­ming up new, block­buster-sized mar­ket …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER